Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 11
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Incidence, associated disease burden and healthcare utilization due to Staphylococcus aureus prosthetic joint infection in European hospitals, the COMBACTE-NET ARTHR-IS multi-centre study

  • Espíndola, Reinaldo
  • Vella, Venanzio
  • Benito, Natividad|||0000-0001-6410-013X
  • Mur, Isabel|||0000-0001-7660-8483
  • Tedeschi, Sara|||0000-0001-9546-2811
  • Zamparini, Eleonora
  • Hendriks, Johannes G. E.
  • Sorlí, Luisa|||0000-0001-9562-514X
  • Murillo Rubio, Oscar|||0000-0001-5776-8422
  • Soldevila-Boixader, Laura|||0000-0003-0649-3785
  • Scarborough, Mathew|||0000-0002-0455-0785
  • Scarborough, Claire
  • Kluytmans, Jan A. J. W.
  • Ferrari, Matteo Carlo
  • Pletz, Mathias|||0000-0001-8157-2753
  • McNamara, Iain R.
  • Escudero Sánchez, Rosa|||0000-0001-5736-8111
  • Arvieux, Cedric
  • Batailler, Cécile
  • Dauchy, Frédéric Antoine
  • Liu, Waiyan
  • Lora-Tamayo, Jaime
  • Praena-Segovia, Julia|||0000-0001-8138-0874
  • Ustianowski, Andrew P.
  • Cinconze, Elisa
  • Pellegrini, Michele|||0000-0001-8505-9260
  • Bagnoli, Fabio
  • Rodríguez-Baño, Jesús|||0000-0001-6732-9001
  • Del-Toro-López, Maria Dolores
The aim of this study was to estimate the incidence, associated disease burden and healthcare utilization due to Staphylococcus aureus prosthetic joint infections (SA-PJI) after primary hip and knee arthroplasty in European centres. This study was conducted in patients who underwent primary hip and knee arthroplasty in 19 European hospitals between 2014 and 2016. The global incidence of PJI and SA-PJI was calculated. The associated disease burden was measured indirectly as infection-related mortality plus loss of function. For healthcare utilization, number and duration of hospitalizations, number and type of surgical procedures, duration of antibiotic treatments, and number of outpatient visits were collected. Subgroup and regression analyses were used to evaluate the impact of SA-PJI on healthcare utilization, controlling for confounding variables. The incidence of PJI caused by any micro-organism was 1.41%, and 0.40% for SA-PJI. Among SA-PJI, 20.7% were due to MRSA with substantial regional differences, and were more frequent in partial hip arthroplasty (PHA). Related deaths and loss of function occurred in 7.0% and 10.2% of SA-PJI cases, respectively, and were higher in patients with PHA. Compared with patients without PJI, patients with SA-PJI had a mean of 1.4 more readmissions, 25.1 more days of hospitalization, underwent 1.8 more surgical procedures, and had 5.4 more outpatient visits, controlling for confounding variables. Healthcare utilization was higher in patients who failed surgical treatment of SA-PJI. This study confirmed that the SA-PJI burden is high, especially in PHA, and provided a solid basis for planning interventions to prevent SA-PJI.
RUC. Repositorio da Universidade da Coruña
Publicación Artículo científico (JournalArticle)

Antiviral and Antiproliferative Potential of Marine Organisms from the Yucatan Peninsula, Mexico

  • Pech-Puch, Dawrin
  • Berastegui-Cabrera, Judith
  • Pérez Povedano, Mar Anabel
  • Villegas-Hernández, Harold
  • Guillén-Hernández, Sergio
  • Cautain, Bastien
  • Reyes, Fernando
  • Pachón, Jerónimo
  • Gómez, Patricia
  • Rodríguez, Jaime
  • Jiménez, Carlos
  • Sánchez Céspedes, Javier
[Abstract] Viral infections are one of the main human health problems in recent decades and the cancer remains one of the most lethal diseases worldwide. The development of new antiviral drugs for the treatment of human adenovirus (HAdV) infections continues to be a challenging goal for medicinal chemistry. There is no specific antiviral drug approved to treat infections caused by HAdV so far and the off-label treatments currently available show great variability in their effectiveness. In relation to cancer, most of the available drugs are designed to act on specific targets by altering the activity of involved transporters and genes. Taking into account the high antiviral and antiproliferative activity against tumor cell lines displayed by some marine natural products reported in the literature, sixty five marine organisms were selected: 51 sponges (Porifera), 13 ascidians (Chordata), and 1 gorgonian (Cnidaria), collected from Yucatan Peninsula, Mexico, to evaluate their antiviral activity against human adenovirus type 5 (HAdV5) and their anticancer properties against five human tumor cell lines, namely human lung carcinoma (A549), human skin melanoma (A2058), hepatocyte carcinoma (HepG2), breast adenocarcinoma (MCF7), and pancreas carcinoma (MiaPaca-2). Eleven extracts displayed anti-HAdV activity being the organic extracts of Dysidea sp., Agelas citrina, Chondrilla sp., Spongia tubulifera, and Monanchora arbuscula the five most active ones. On the other hand, 24 extracts showed antiproliferative activity against at least one tumor cell line, being the extracts of the ascidian Eudistoma amanitum and the sponge Haliclona (Rhizoniera) curacaoensis the most active ones. This work constitutes the first wide antiviral and antiproliferative screening report of extracts from the marine sponges, ascidians, and a gorgonian collected from the Yucatan Peninsula, Mexico., This work was supported by Grants RTI2018-093634-B-C22 and RTC-2016-4611-1 (AEI/FEDER, EU) from the State Agency for Research (AEI) of Spain, both co-funded by the FEDER Programme from the European Union, BLUEBIOLAB (0474_BLUEBIOLAB_1_E), Programme INTERREG V A of Spain-Portugal (POCTEP). The study was also funded by projects GRC2018/039 and Agrupación Estratégica CICA-INIBIC ED431E 2018/03 (Consejería de Educación, Universidad y Formación Profesional de la Junta de Galicia) from the Xunta de Galicia (autonomous government of the region). DP-P received a fellowship from the program National Council of Science and Technology (CONACYT) of Mexico and the Secretariat of Research, Innovation and Higher Education (SIIES) of Yucatan (Mexico). Also supported by Instituto de Salud Carlos III, Ministerio de Economía, Industria y Competitividad, Spanish Network for Research in Infectious Diseases (REIPI RD16/0016/0009) – co-financed by “A way to achieve Europe” ERDF, the Instituto de Salud Carlos III, Proyectos de Desarrollo Tecnológico en Salud (DTS17/00130 and PI18/01191), and the Spanish Adenovirus Network (AdenoNet, BIO2015/68990-REDT). JS-C is a researcher belonging to the program “Nicolás Monardes” (C-0059-2018), Servicio Andaluz de Salud, Junta de Andalucía, Spain. The antiproliferative studies were financed with internal funds from Fundación MEDINA, Xunta de Galicia; 0474_BLUEBIOLAB_1_E, Xunta de Galicia; GRC2018/039, Xunta de Galicia; ED431E 2018/03, Junta de Andalucía; C-0059-2018
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Impact of SARS-CoV-2 RNAemia and other risk factors on long-COVID: A prospective observational multicentre cohort study

  • Rombauts, Alexander
  • Infante, Carmen
  • Álamo Martínez de Lagos, Mikel del
  • Alba, Jorge
  • Valiente, Adoración
  • Donado-Mazarrón, Carla
  • Carretero-Ledesma, Marta
  • Rodríguez-Álvarez, Regino José
  • Omatos, Sonia
  • Palacios-Baena, Zaira Raquel
  • Abelenda, Gabriela
  • Silva-Sánchez, María del Mar
  • Goikoetxea-Aguirre, Josune
  • Oteo, José Antonio
  • Rodríguez-Baño, Jesús
  • Cordero, Elisa
  • Gudiol, Carlota
  • Sánchez-Céspedes, Javier
  • Carratalà, Jordi
As the COVID-19 pandemic has progressed, long-COVID has emerged as a major problem that poses a significant challenge for attending physicians and health care policy makers. Therefore, we read with much interest the recently published unicentre study in the Journal of Infection by Righi et al.,1 carried out on 465 adult COVID-19 patients (235 [50.5%] hospital-admitted) followed-up during nine months, concluding that those with advanced age, intensive care unit (ICU) admission, and multiple symptoms at onset were more likely to have long-term COVID-19 symptoms, with negative impact on physical and mental wellbeing. Other studies have found that female gender, age, longer hospital stay, pre-existing hypertension, cardiovascular disease, diabetes, chronic obstructive pulmonary disease, smoking, obesity, and chronic alcoholism increase the likelihood of long-COVID.2,3 It is known that SARS-CoV-2 RNAemia is a predictor of COVID-19 severity and in-hospital complications.4,5 However, to the best of our knowledge, only two studies have assessed, up to one or three months after the acute COVID-19 onset, whether SARS-CoV-2 RNAemia may have an impact on long-COVID,6,7 both finding that RNAemia at presentation might predict the persistence of symptoms. However, these studies did not provide information regarding long-COVID symptoms nor the association with SARS-CoV-2 RNAemia beyond three months, and could not differentiate between “true” long-COVID and the convalescence phase of the SARS-CoV-2 infection., A.R. has received a predoctoral research grant from the Instituto de Salud Carlos III, Spanish Ministry of Science, Innovation and Universities, (PFIS grant FI18/00183). G.A.A. reports a predoctoral research grant from the 201808-10 project, funded by La Marató de TV3. This study was supported by the Instituto de Salud Carlos III, Subdirección General de Redes y Centros de Investigación Cooperativa, Ministerio de Economía, Industria y Competitividad, the Spanish Network for Research in Infectious Diseases (REIPI, RD16/0016/0001, RD16/0016/0005, RD16/0016/0009, RD16/0016/0013)-co-financed by the European Development Regional Fund, A way to achieve Europe, Operative program Intelligent Growth 2014-2020, and the Centro de Investigación Biomédica en Red de Enfermedades Infecciosas (CIBERINFEC) [CB21/13/00009; CB21/13/00006], Madrid, Spain. J.S.C. and E.C. received grants from the Instituto de Salud Carlos III, Ministerio de Ciencia e Innovación, Proyectos de Investigación sobre el SARS-CoV-2 y la enfermedad COVID-19 (COV20/00580; COV20/00370). J.S.C. is a researcher belonging to the program “Nicolás Monardes” (C-0059–2018), Servicio Andaluz de Salud, Junta de Andalucía, Spain. Samples and data from patients included in this study from the Hospital Universitario Cruces (Bizkaia, Spain) were provided by the Basque Biobank (www.biobancovasco.org) and were processed following standard operation procedures with appropriate approval of the Ethical and Scientific Committees., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Incidence, associated disease burden and healthcare utilization due to Staphylococcus aureus prosthetic joint infection in European hospitals: the COMBACTE-NET ARTHR-IS multi-centre study

  • Espíndola, Reinaldo
  • Vella, Venanzio
  • Benito, Natividad
  • Mur, Isabel
  • Tedeschi, Sara
  • Zamparini, Eleonora
  • Hendriks, Johannes G. E.
  • Sorlí, Luisa
  • Murillo, Óscar
  • Soldevila-Boixader, Laura
  • Scarborough, Mathew
  • Scarborough, Claire
  • Kluytmans, Jan
  • Ferrari, Matteo Carlo
  • Pletz, Mathias W.
  • Mcnamara, Iain
  • Escudero-Sánchez, Rosa
  • Arvieux, Cédric
  • Batailler, Cecile
  • Dauchy, Frédéric-Antoine
  • Liu, Wai-Yan
  • Lora-Tamayo, Jaime
  • Praena-Segovia, Julia
  • Ustianowski, Andrew
  • Cinconze, Elisa
  • Pellegrini, Michele
  • Bagnoli, Fabio
  • Rodríguez-Baño, Jesús
  • Toro, María Dolores del
© 2023 The Author(s). Published by Elsevier Ltd on behalf of The Healthcare Infection Society. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/)., [Background] The aim of this study was to estimate the incidence, associated disease burden and healthcare utilization due to Staphylococcus aureus prosthetic joint infections (SA-PJI) after primary hip and knee arthroplasty in European centres., [Methods] This study was conducted in patients who underwent primary hip and knee arthroplasty in 19 European hospitals between 2014 and 2016. The global incidence of PJI and SA-PJI was calculated. The associated disease burden was measured indirectly as infection-related mortality plus loss of function. For healthcare utilization, number and duration of hospitalizations, number and type of surgical procedures, duration of antibiotic treatments, and number of outpatient visits were collected. Subgroup and regression analyses were used to evaluate the impact of SA-PJI on healthcare utilization, controlling for confounding variables., [Results] The incidence of PJI caused by any micro-organism was 1.41%, and 0.40% for SA-PJI. Among SA-PJI, 20.7% were due to MRSA with substantial regional differences, and were more frequent in partial hip arthroplasty (PHA). Related deaths and loss of function occurred in 7.0% and 10.2% of SA-PJI cases, respectively, and were higher in patients with PHA. Compared with patients without PJI, patients with SA-PJI had a mean of 1.4 more readmissions, 25.1 more days of hospitalization, underwent 1.8 more surgical procedures, and had 5.4 more outpatient visits, controlling for confounding variables. Healthcare utilization was higher in patients who failed surgical treatment of SA-PJI., [Conclusions] This study confirmed that the SA-PJI burden is high, especially in PHA, and provided a solid basis for planning interventions to prevent SA-PJI., This work was supported by the Innovative Medicines Initiative Joint Undertaking (grant agreement No. 115523), COMBACTE-NET consortium (European Union FP7/2007–2013 and GlaxoSmithKline Biologicals SA, as EFPIA partner). R.E., L.S, O.M., R.E.-S., J.L.-T., J.P., J.R.-B. and M.D.del T. are members of the Spanish Network for Research in Infectious Diseases (REIPI), supported by the Plan Nacional de I+D+i 2013–2016 and Instituto de Salud Carlos III, Subdirección General de Redes y Centros de Investigación Cooperativa, Ministerio de Ciencia, Innovación y Universidades, Spanish Network for Research in Infectious Diseases (REIPI RD16/0016/0001; 0002; 0005; 0009; 0011; 0015), co-financed by European Development Regional Fund ‘A way to achieve Europe’, Operative Program Intelligence Growth 2014–2020. M.W.P. was partly supported by the German Research Foundation (GRK 2723, project number 444711651)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Prepandemic viral community-acquired pneumonia: Diagnostic sensitivity and specificity of nasopharyngeal swabs and performance of clinical severity scores

  • Berastegui-Cabrera, Judith
  • Aguilar Guisado, Manuela
  • Crespo-Rivas, Juan Carlos
  • López-Verdugo, Macarena
  • Merino Díaz, Laura
  • Escoresca-Ortega, Ana
  • Calero-Acuña, Carmen
  • Carrasco Hernández, Laura
  • Toral-Marín, Javier Ignacio
  • Abad Arranz, María
  • Ramírez-Duque, Nieves
  • Barón Franco, Bosco
  • Pachón, Jerónimo
  • Álvarez-Marín, Rocío
  • Sánchez-Céspedes, Javier
© 2022 The Authors. Journal of Medical Virology published by Wiley Periodicals LLC. This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made., The objectives of this work were to assess the diagnostic sensitivity and specificity of nasopharyngeal (NP) swabs for viral community-acquired pneumonia (CAP) and the performance of pneumonia severity index (PSI) and CURB-65 severity scores in the viral CAP in adults. A prospective observational cohort study of consecutive 341 hospitalized adults with CAP was performed between January 2018 and March 2020. Demographics, comorbidities, symptoms/signs, analytical data, severity scores, antimicrobials, and outcomes were recorded. Blood, NP swabs, sputum, and urine samples were collected at admission and assayed by multiplex real time-PCR, bacterial cultures, and Streptococcus pneumoniae and Legionella pneumophila antigens detection, to determine the etiologies and quantify the viral load. The etiology was identified in 174 (51.0%) patients, and in 85 (24.9%) it was viral, the most frequent rhinovirus and influenza virus. The sensitivity of viral detection in sputum (50.7%) was higher than in NP swabs (20.9%). Compared with sputum, the positive predictive value and specificity of NP swabs for viral diagnosis were 95.8% and 96.9%, respectively. Performance of PSI and CURB-65 scores in all CAP with etiologic diagnosis were as expected, with mortality associated with higher values, but they were not associated with mortality in patients with viral pneumonia. NP swabs have lower sensitivity but high specificity for the diagnosis of viral CAP in adults compared with sputum, reinforcing the use NP swabs for the diagnostic etiology work-up. The PSI and CURB-65 scores did not predict mortality in the viral CAP, suggesting that they need to be updated scores based on the identification of the etiological agent., This work was supported by National Plan R + D + I 2013–2016 and Instituto de Salud Carlos III, Subdirección General de Redes y Centros de Investigación Cooperativa, Ministry of Economy, Industry, and Competitiveness, Spanish Network for Research in Infectious Diseases [REIPI RD16/0016/0009]; cofinanced by European Development Regional Fund “A way to achieve Europe”, Operative program Intelligent Growth 2014–2020; and supported by the grant PI17/01055 from the Instituto de Salud Carlos III. MAG, RAM and JSC [grant number CB21/13/00006] also received support from the CIBER de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III, Ministerio de Ciencia e Innovación, cofinanced by the European Development Regional Fund. J.S.C. is a researcher belonging to the program “Nicolás Monardes” (C-0059-2018), Servicio Andaluz de Salud, Junta de Andalucía, Spain., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

RecA inactivation as a strategy to reverse the heteroresistance phenomenon in clinical isolates of Escherichia coli

  • Díaz-Díaz, Sara
  • Yerbes, Pilar
  • Recacha, Esther
  • Gregorio-Iaria, Belén de
  • Pulido, Marina R.
  • Romero-Muñoz, María
  • Docobo-Pérez, Fernando
  • Pascual, Álvaro
  • Rodríguez-Martínez, José-Manuel
RecA inhibition could be an important strategy to combat antimicrobial resistance because of its key role in the SOS response, DNA repair and homologous recombination contributing to bacterial survival. This study evaluated the impact of RecA inactivation on heteroresistance in clinical isolates of Escherichia coli and their corresponding recA-deficient isogenic strains to multiple classes of antimicrobial agents. A high frequency (>30%) of heteroresistance was observed in this collection of clinical isolates. Deletion of the recA gene led to a marked reduction in heteroresistant subpopulations, especially against quinolones or β-lactams. The molecular basis of heteroresistance was associated with an increase in copy number of plasmid-borne resistance genes (blaTEM-1B) or tandem gene amplifications (qnrA1). Of note, in the absence of the recA gene, the increase in copy number of resistance genes was suppressed. This makes the recA gene a promising target for combating heteroresistance., This work was supported by the Plan Nacional de I+D+i 2013–2016 and the Instituto de Salud Carlos III [projects PI17/01501 and PI20/00239], Subdirección General de Redes y Centros de Investigación Cooperativa, Ministerio de Economía, Industria y Competitividad, Spanish Network for Research in Infectious Diseases (REIPI) [RD16/0016/0001 and RD16/0016/0009]—co‐financed by European Development Regional Fund ‘A way to achieve Europe’, Operative program Intelligent Growth 2014–2020. SD-D is supported by a PFIS grant from the Instituto de Salud Carlos III [FI18/00086], co-funded by ESF ‘Investing in your future’. ER is supported by a Juan Rodés Grant from the Instituto de Salud Carlos III [JR21/00030], co-funded by ESF ‘Investing in your future’. MRP is supported by a VIPPI-US fellowship from the University of Seville. MR-M is supported by the Fondo Social Europeo [EJ5-91, Programa Iniciativa de Empleo Juvenil]., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Inhibition of adenovirus transport from the endosome to the cell nucleus by rotenone

  • Balsera-Manzanero, María
  • Ghirga, Francesca
  • Ruiz-Molina, Ana
  • Mori, Mattia
  • Pachón, Jerónimo
  • Botta, Bruno
  • Cordero-Matía, Elisa
  • Quaglio, Deborah
  • Sánchez-Céspedes, Javier
© 2024 Balsera-Manzanero, Ghirga, Ruiz-Molina, Mori, Pachón, Botta, Cordero, Quaglio and Sánchez-Céspedes. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms., Regardless of the clinical impact of human adenovirus (HAdV) infections in the healthy population and its high morbidity in immunosuppressed patients, a specific treatment is still not yet available. In this study, we screened the CM1407 COST Action’s chemical library, comprising 1,233 natural products to identify compounds that restrict HAdV infection. Among them, we identified rotenolone, a compound that significantly inhibited HAdV infection. Next, we selected four isoflavonoid-type compounds (e.g., rotenone, deguelin, millettone, and tephrosin), namely rotenoids, structurally related to rotenolone in order to evaluate and characterized in vitro their antiviral activities against HAdV and human cytomegalovirus (HCMV). Their IC50 values for HAdV ranged from 0.0039 µM for rotenone to 0.07 µM for tephrosin, with selective indices ranging from 164.1 for rotenone to 2,429.3 for deguelin. In addition, the inhibition of HCMV replication ranged from 50% to 92.1% at twice the IC50 concentrations obtained in the plaque assay for each compound against HAdV. Our results indicated that the mechanisms of action of rotenolone, deguelin, and tephrosin involve the late stages of the HAdV replication cycle. However, the antiviral mechanism of action of rotenone appears to involve the alteration of the microtubular polymerization, which prevents HAdV particles from reaching the nuclear membrane of the cell. These isoflavonoid-type compounds exert high antiviral activity against HAdV at nanomolar concentrations, and can be considered strong hit candidates for the development of a new class of broad-spectrum antiviral drugs., The author(s) declare financial support was received for the research, authorship, and/or publication of this article. This research was partially supported by EU funding within the NextGenerationEU-MUR PNRR Extended Partnership initiative on Emerging Infectious Diseases (Project no. PE00000007, INF-ACT). This work was partially supported by the Plan Nacional de I + D + i 2013–2016 and Instituto de Salud Carlos III, Subdirección General de Redes y Centros de Investigación Cooperativa, Ministerio de Economía, Industria y Competitividad, Spanish Network for Research in Infectious Diseases (REIPI RD16/0016/0009), cofinanced by the European Development Regional Fund “A way to achieve Europe,” Operative program Intelligent Growth 20142020, the Instituto de Salud Carlos III, Proyectos de Investigación en Salud (PI18/01191), and Proyectos de Desarrollo Tecnológico en Salud (DTS20/00010). JS-C and EC (CB21/13/00006) also were supported by CIBERINFEC—Consorcio Centro de Investigación Biomédica en Red, Instituto de Salud Carlos III, Ministerio de Ciencia e Innovación and Unión Europea–NextGenerationEU. JS-C is a researcher belonging to the program “Nicolás Monardes” (C-0059-2018), Servicio Andaluz de Salud, Junta de Andalucía, Spain., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Effectiveness of oral step-down therapy and early oral switch for bloodstream infections caused by Enterobacterales: A post hoc emulation trial of the SIMPLIFY trial

  • Rando, Emanuele
  • Delgado-Valverde, Mercedes
  • Goikoetxea-Aguirre, Josune
  • Guio Carrión, Laura
  • Blanco-Vidal, María José
  • Barrios Andrés, José Luis
  • Pérez-Rodríguez, María Teresa
  • Martínez-Lamas, Lucía
  • Arnaiz de Las Revillas, Francisco
  • Armiñanzas, Carlos
  • Ruiz de Alegría, Carlos
  • Jiménez-Aguilar, Patricia
  • Martínez-Rubio, María del Carmen
  • Sáez-Béjar, Carmen
  • Cuevas, Carmen de las
  • Martín-Aspas, Andrés
  • Galán, Fátima
  • Yuste, José Ramón
  • Leiva-León, José
  • Bou, Germán
  • Capón González, Patricia
  • Boix-Palop, Lucía
  • Xercavins-Valls, Mariona
  • Goenaga Sánchez, Miguel Ángel
  • Anza, Diego Vicente
  • Castón, Juan José
  • Recio Rufián, Manuel
  • Merino, Esperanza
  • Rodríguez, Juan Carlos
  • Loeches, Belén
  • Rosso-Fernández, Clara
  • Bravo-Ferrer, José María
  • Retamar-Gentil, Pilar
  • Rodríguez-Baño, Jesús
  • López-Cortés, Luis Eduardo
[Objectives] We investigated the effectiveness of early oral switch for treating Enterobacterales bloodstream infection (BSI) by performing a post hoc emulation trial of the SIMPLIFY trial., [Methods] We conducted a post hoc analysis of a randomized controlled trial. We specified the target trial characteristics selecting patients who achieved clinical stability on day 5. We categorized patients into those who switched on day 5 and those who continued intravenously. The primary outcome was clinical cure at the test of cure. We set a propensity score for being switched on day 5 to reduce confounding. We ran simple, not-propensity-adjusted, and propensity-adjusted logistic regression models to ascertain the association of switch on day 5 with clinical cure., [Results] Among 303 patients who achieved clinical stability on day 5, 110 (36.3%) were switched orally on day 5, and 193 (63.7%) were kept intravenously. We detected no difference in clinical cure between those switched on day 5 and those continued intravenously (risk ratios 1.04, 95% confidence intervals [CI] 0.98-1.10). Propensity-adjusted analysis did not show an association between day 5 switch and clinical cure (OR 2.10, 95% CI 0.96-7.41)., [Conclusion] Oral step-down therapy on day 5 was not associated with worse clinical cure for Enterobacterales BSI., The study was funded by the Plan Nacional de I+D+i 2013‐2016 and Instituto de Salud Carlos III, Subdirección General de Redes y Centros de Investigación Cooperativa, Ministerio de Ciencia, Innovación y Universidades, Spanish Network for Research in Infectious Diseases (REIPI RD16/0016/0001; 0002; 0003; 0005; 0007; 0008; 0009; 0011; 0012; 0015); Spanish Clinical Research and Clinical Trials Platform, (SCReN, PT13/0002/0010 and PT17/0017/0012, and PI15/00439), co‐financed by European Union; European Development Regional Fund “A way to achieve Europe,” Operative Program Intelligence Growth 2014‐2020., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Fosfomycin in bacteraemic urinary tract infection due to multidrug-resistant Escherichia coli: insights of post hoc DOOR analysis of the FOREST trial

  • Sojo-Dorado, Jesús
  • López-Hernández, Inmaculada
  • Gutiérrez-Gutiérrez, Belén
  • Rosa-Riestra, Sandra de la
  • Docobo-Pérez, Fernando
  • Hernánez-Torres, Alicia
  • Pascual, Álvaro
  • Rodríguez-Baño, Jesús
[Purpose] A post hoc analysis of data from a previously published clinical trial was conducted using the desirability of outcome ranking (DOOR) methodology with the aim provide additional information on the use of fosfomycin for the treatment of bacteraemic urinary tract infection (BUTI) caused by multi-drug-resistant (MDR) E. coli., [Methods] Three DOOR systems with five, six and seven categories, respectively were developed. Safety and efficacy were prioritised in all rankings, but step down to oral therapy and exposure to antibiotics with lower ecological impact were also considered in DOOR-6 and DOOR-7. The probability that a patients assigned to fosfomycin was classified into a more desirable outcome category was calculated for the three DOOR definitions. Subgroups analyses and an ordinal logistic regression model were also performed., [Results] Data from 143 participants were analysed. The probability of having a more desirable outcome after treatment with fosfomycin versus the comparators was 0.44 (95% CI 0.36 − 0.52) for DOOR-5; 0.50 (95% IC 0.42 − 0.58) using DOOR-6 and 0.61 (95% CI 0.53–0.69) with DOOR-7. In subgroups, the highest probability of having a better DOOR with fosfomycin was seen in the clinically evaluable population and among patients without chronic heart disease or renal insufficiency for the DOOR-7 definition., [Conclusions] DOOR analysis could be applied to the FOREST trial data; the results were somehow different for the different DOOR systems used. Overall, fosfomycin was favoured when oral step-down treatment and use of antibiotics with lower ecological impact were included., The study was funded by grants RD16/0016/0001, 0002, 0003, 0005, 0007, 0008, 0009, 0011, 0012, and 0015 from Plan Nacional de Investigación, Desarrollo e Innovación (I + D + i) 2013 to 2016 and the Instituto de Salud Carlos III, Subdirección General de Redes y Centros de Investigación Cooperativa, Ministerio de Ciencia, Innovación y Universidades, Spanish Network for Research in Infectious Diseases (REIPI); PT13/0002/0010 and PT17/0017/0012 from the Spanish Clinical Research and Clinical Trials Platform (SCReN); and PI 13/01282 co-financed by the European Development Regional Fund “A Way to Achieve Europe” and Operative Program Intelligence Growth 2014 to 2020. The funders had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication., Peer reviewed
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Rates and Predictors of Treatment Failure in Staphylococcus aureus Prosthetic Joint Infections According to Different Management Strategies, A Multinational Cohort Study-The ARTHR-IS Study Group

  • Espíndola, Reinaldo
  • Vella, Venanzio
  • Benito, Natividad|||0000-0001-6410-013X
  • Mur, Isabel|||0000-0001-7660-8483
  • Tedeschi, Sara|||0000-0001-9546-2811
  • Zamparini, Eleonora
  • Hendriks, Johannes G. E.
  • Sorlí, Luisa|||0000-0001-9562-514X
  • Murillo Rubio, Oscar|||0000-0001-5776-8422
  • Soldevila-Boixader, Laura|||0000-0003-0649-3785
  • Scarborough, Mathew|||0000-0002-0455-0785
  • Scarborough, Claire
  • Kluytmans, Jan|||0000-0003-2665-6844
  • Ferrari, Mateo Carlo
  • Pletz, Mathias|||0000-0001-8157-2753
  • Mcnamara, Iain
  • Escudero Sánchez, Rosa|||0000-0001-5736-8111
  • Arvieux, Cedric
  • Batailler, Cécile
  • Dauchy, Frédéric Antoine
  • Liu, Wai-Yan
  • Lora-Tamayo, Jaime
  • Praena, Julia
  • Ustianowski, Andrew
  • Cinconze, Elisa
  • Pellegrini, Michele|||0000-0001-8505-9260
  • Rodríguez-Baño, Jesús|||0000-0001-6732-9001
  • del Toro López, María Dolores|||0000-0002-4935-8754
Guidelines have improved the management of prosthetic joint infections (PJI). However, it is necessary to reassess the incidence and risk factors for treatment failure (TF) of Staphylococcus aureus PJI (SA-PJI) including functional loss, which has so far been neglected as an outcome. A retrospective cohort study of SA-PJI was performed in 19 European hospitals between 2014 and 2016. The outcome variable was TF, including related mortality, clinical failure and functional loss both after the initial surgical procedure and after all procedures at 18 months. Predictors of TF were identified by logistic regression. Landmark analysis was used to avoid immortal time bias with rifampicin when debridement, antibiotics and implant retention (DAIR) was performed. One hundred twenty cases of SA-PJI were included. TF rates after the first and all surgical procedures performed were 32.8% and 24.2%, respectively. After all procedures, functional loss was 6.0% for DAIR and 17.2% for prosthesis removal. Variables independently associated with TF for the first procedure were Charlson ≥ 2, haemoglobin < 10 g/dL, bacteraemia, polymicrobial infection and additional debridement(s). For DAIR, TF was also associated with a body mass index (BMI).
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Effectiveness of Fosfomycin for the Treatment of Multidrug-Resistant Escherichia coli Bacteremic Urinary Tract Infections, A Randomized Clinical Trial

  • Sojo-Dorado, Jesús
  • López-Hernández, I.
  • Rosso-Fernandez, C.
  • Palacios-Baena, Z.R.
  • Hernández-Torres, A.
  • Merino de Lucas, Esperanza|||0000-0003-3854-4874
  • Escolà-Vergé, Laura|||0000-0002-5608-3090
  • Bereciartua, Elena|||0000-0002-8603-779X
  • García-Vázquez, E.
  • Pintado, Vicente
  • Boix-Palop, Lucía|||0000-0002-4080-0008
  • Natera-Kindelán, C.
  • Sorlí, Luisa|||0000-0001-9562-514X
  • Borrell, Nuria
  • Giner-Oncina, L.
  • Amador-Prous, C.
  • Shaw, Evelyn|||0000-0002-1882-1259
  • Jover-Saenz, Alfredo|||0000-0001-5207-7200
  • Molina, J.
  • Martínez-Alvarez, R.M.
  • Dueñas, C.J.
  • Calvo-Montes, J.
  • Silva, J.T.
  • Cárdenes, M.A.
  • Lecuona, M.
  • Pomar, Virginia|||0000-0002-8473-5834
  • Valiente De Santis, L.
  • Yagüe-Guirao, G.
  • Lobo-Acosta, M.A.
  • Merino-Bohórquez, V.
  • Pascual, A.
  • Rodríguez-Baño, Jesús|||0000-0001-6732-9001
  • Almirante Gragera, Benito|||0000-0002-1189-2361
  • Mirelis, Beatriz
  • Pigrau, Carlos|||0000-0003-4232-4049
  • Viñado, Belén|||0000-0001-6212-5886
  • Puig-Asensio, Mireia|||0000-0002-0722-2218
  • Ardanuy, Carmen|||0000-0003-0225-607X
  • Pujol, Miquel|||0000-0002-6475-6208
The consumption of broad-spectrum drugs has increased as a consequence of the spread of multidrug-resistant (MDR) Escherichia coli. Finding alternatives for these infections is critical, for which some neglected drugs may be an option. To determine whether fosfomycin is noninferior to ceftriaxone or meropenem in the targeted treatment of bacteremic urinary tract infections (bUTIs) due to MDR E coli. Design, Setting, and Participants: This multicenter, randomized, pragmatic, open clinical trial was conducted at 22 Spanish hospitals from June 2014 to December 2018. Eligible participants were adult patients with bacteremic urinary tract infections due to MDR E coli; 161 of 1578 screened patients were randomized and followed up for 60 days. Data were analyzed in May 2021. Patients were randomized 1 to 1 to receive intravenous fosfomycin disodium at 4 g every 6 hours (70 participants) or a comparator (ceftriaxone or meropenem if resistant; 73 participants) with the option to switch to oral fosfomycin trometamol for the fosfomycin group or an active oral drug or parenteral ertapenem for the comparator group after 4 days. Main Outcomes and Measures: The primary outcome was clinical and microbiological cure (CMC) 5 to 7 days after finalization of treatment; a noninferiority margin of 7% was considered. Among 143 patients in the modified intention-to-treat population (median [IQR] age, 72 [62-81] years; 73 [51.0%] women), 48 of 70 patients (68.6%) treated with fosfomycin and 57 of 73 patients (78.1%) treated with comparators reached CMC (risk difference, -9.4 percentage points; 1-sided 95% CI, -21.5 to ∞ percentage points; P =.10). While clinical or microbiological failure occurred among 10 patients (14.3%) treated with fosfomycin and 14 patients (19.7%) treated with comparators (risk difference, -5.4 percentage points; 1-sided 95% CI, -∞ to 4.9; percentage points; P =.19), an increased rate of adverse event-related discontinuations occurred with fosfomycin vs comparators (6 discontinuations [8.5%] vs 0 discontinuations; P =.006). In an exploratory analysis among a subset of 38 patients who underwent rectal colonization studies, patients treated with fosfomycin acquired a new ceftriaxone-resistant or meropenem-resistant gram-negative bacteria at a decreased rate compared with patients treated with comparators (0 of 21 patients vs 4 of 17 patients [23.5%]; 1-sided P =.01). This study found that fosfomycin did not demonstrate noninferiority to comparators as targeted treatment of bUTI from MDR E coli; this was due to an increased rate of adverse event-related discontinuations. This finding suggests that fosfomycin may be considered for selected patients with these infections. ClinicalTrials.gov Identifier: NCT02142751.